If you made any changes in Pure these will be visible here soon.

Personal profile

Education/Academic qualification

Doctor of Philosophy, University of London

Bachelor of Science, University of Glasgow


  • RM Therapeutics. Pharmacology
  • drug discovery

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Drug Discovery Medicine & Life Sciences
Trypanosoma brucei brucei Medicine & Life Sciences
Screening Chemical Compounds
Leishmania donovani Medicine & Life Sciences
Parasites Medicine & Life Sciences
Calcitonin Gene-Related Peptide Medicine & Life Sciences
Trypanosoma cruzi Medicine & Life Sciences
Receptors, Prostaglandin E, EP4 Subtype Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2022

Research Output 1992 2018

4 Citations

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

Wyllie, S., Thomas, M., Patterson, S., Crouch, S., De Rycker, M., Lowe, R., Gresham, S., Urbaniak, M. D., Otto, T. D., Stojanovski, L., Simeons, F. R. C., Manthri, S., MacLean, L. M., Zuccotto, F., Homeyer, N., Pflaumer, H., Boesche, M., Sastry, L., Connolly, P., Albrecht, S. & 12 othersBerriman, M., Drewes, G., Gray, D. W., Ghidelli-Disse, S., Dixon, S., Fiandor, J. M., Wyatt, P. G., Ferguson, M. A. J., Fairlamb, A. H., Miles, T. J., Read, K. D. & Gilbert, I. H., 9 Aug 2018, In : Nature. 560, 7717, p. 192-197 6 p.

Research output: Contribution to journalArticle

Open Access
Visceral Leishmaniasis
Cyclin-Dependent Kinases
Pharmaceutical Preparations
1 Citations

Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery

MacLean, L., Thomas, J., Lewis, M. D., Cotillo, I., Gray, D. & De Rycker, M., 12 Jul 2018, In : PLoS Neglected Tropical Diseases. 12, 7, p. 1-22 22 p., e0006612.

Research output: Contribution to journalArticle

Open Access
Chagas Disease
Trypanosoma cruzi
Drug Discovery

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

Thomas, M. G., De Rycker, M., Ajakane, M., Albrecht, S., Álvarez-Pedraglio, A. I., Boesche, M., Brand, S., Campbell, L., Cantizani-Perez, J., Cleghorn, L. A. T., Copley, R. C. B., Crouch, S. D., Daugan, A., Drewes, G., Ferrer, S., Ghidelli-Disse, S., Gonzalez, S., Gresham, S. L., Hill, A. P., Hindley, S. J. & 32 othersLowe, R. M., MacKenzie, C. J., MacLean, L., Manthri, S., Martin, F., Miguel-Siles, J., Nguyen, V. L., Norval, S., Osuna-Cabello, M., Woodland, A., Patterson, S., Pena, I., Quesada-Campos, M. T., Reid, I. H., Revill, C., Riley, J., Ruiz-Gomez, J. R., Shishikura, Y., Simeons, F. R. C., Smith, A., Smith, V. C., Spinks, D., Stojanovski, L., Thomas, J., Thompson, S., Underwood, T., Gray, D. W., Fiandor, J. M., Gilbert, I. H., Wyatt, P. G., Read, K. D. & Miles, T. J., 20 Dec 2018, In : Journal of Medicinal Chemistry. 23 p.

Research output: Contribution to journalArticle

Visceral Leishmaniasis
Leishmania major
Leishmania donovani
Standard of Care
72 Citations
Open Access
Drug Discovery
Public Health
Neglected Diseases
Disease Eradication
African Trypanosomiasis
9 Citations

Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase

Nakazawa Hewitt, S., Dranow, D. M., Horst, B. G., Abendroth, J. A., Forte, B., Hallyburton, I., Jansen, C., Baragana, B., Choi, R., Rivas, K., Hulverson, M. A., Dumais, M., Edwards, T. E., Lorimer, D. D., Fairlamb, A., Gray, D., Read, K., Lehane, A. M., Kirk, K., Myler, P. J. & 6 othersWernimont, A., Walpole, C., Stacy, R., Barrett, L., Gilbert, I. H. & Van Voorhis, W. C., 13 Jan 2017, In : ACS Infectious Diseases. 3, 1, p. 34-44 11 p.

Research output: Contribution to journalArticle

Open Access
Pharmaceutical Chemistry
Plasmodium falciparum
X Ray Crystallography

Activities 2011 2019

  • 8 Other
  • 2 Invited talk
  • 1 Membership of panel

Action Medical Research - Scientific Advisory Panel

David Gray (Member)
2019 → …

Activity: Other activity typesOther

Member of MRC/AZ Centre for Lead Discovery (CLD)

David Gray (Member)
Jan 2017 → …

Activity: Other activity typesOther

Global Antimicrobial Resistance Investment Fund (GAMRIF) panel

David Gray (Member)

Activity: Other activity typesOther

Dundee Drug Discovery Unit, Diversity screening for tropical diseases

David Gray (Speaker)
Jul 2014

Activity: Talk or presentation typesInvited talk

external review of infrastructure grants

David Gray (Reviewer)
1 Jan 20131 May 2013

Activity: Other activity typesOther


Early-stage drug discovery of HIV-1 frameshifting modulators

Author: Fernandes, A. B., 2015

Supervisor: Gray, D. (Supervisor) & Wilson, S. (External person) (Supervisor)

Student thesis: Doctoral ThesisDoctor of Philosophy